US equities |
NVDA $204.64 ▼-4.22% INTC $65.76 ▼-28.58% MU $884.74 ▼-5.30% AMZN $240.35 ▼-1.41% AAPL $344.63 ▼-1.23% SNDK $1,150.89 ▼-13.47% AMD $504.80 ▼-10.88% MSFT $521.91 ▼-1.55%
FinancialContent

Articles published by CytRx Corporation

News headline image
CytRx Corporation Relaunches as LadRx Corporation
From CytRx Corporation
Via Business Wire
Tickers CYTR
News headline image
European Patent Office Awards CytRx Key Patent
From CytRx Corporation
Via Business Wire
Tickers CYTR
News headline image
CytRx Welcomes Cary J. Claiborne to the CytRx Board of Directors
From CytRx Corporation
Via Business Wire
Tickers CYTR
News headline image
CytRx Announces Distribution of Series D Preferred Stock to Holders of Its Common Stock
From CYTRX CORPORATION
Via Business Wire
Tickers CYTR
News headline image
CytRx Highlights Strategic Purchase of Arimoclomol by KemPharm, Inc.
From CytRx Corporation
Via Business Wire
Tickers CYTR
News headline image
CytRx Partners with Oncology Development Expert to Advance LADR Platform
From CytRx Corporation
Via Business Wire
Tickers CYTR
News headline image
CytRx Issues Open Letter to Stockholders Regarding Recent Corporate Progress
From CytRx Corporation
Via Business Wire
Tickers CYTR
News headline image
CytRx Comments on Orphazyme's Update on European Union Regulatory Review of Arimoclomol in Niemann-Pick Disease Type C
From CytRx Corporation
Via Business Wire
Tickers CYTR
News headline image
CytRx Highlights Orphazyme's Update on Planned NDA Resubmission for Arimoclomol in Niemann-Pick Disease Type C
From CytRx Corporation
Via Business Wire
Tickers CYTR
News headline image
CytRx to Hold Town Hall for Stockholders on Thursday, January 20th
From CytRx Corporation
Via Business Wire
Tickers CYTR
News headline image
CytRx to Participate in the H.C. Wainwright BioConnect Virtual Conference
From CytRx Corporation
Via Business Wire
Tickers CYTR
News headline image
CytRx Announces the Appointment of Dr. Stephen Snowdy as Chief Executive Officer
From CytRx Corporation
Via Business Wire
Tickers CYTR
News headline image
CytRx Highlights ImmunityBio's Use of Aldoxorubicin in Ongoing Clinical Studies for Various Forms of Cancer
From CytRx Corporation
Via Business Wire
Tickers CYTR
News headline image
CytRx Provides a Bold Vision on Centurion BioPharma's Plans for a State-of-the-Art Cancer Center in Las Vegas, Nevada
From CytRx Corporation
Via Business Wire
Tickers CYTR
News headline image
CytRx Comments on Quarterly Results and Recent Strategic Initiatives
From CytRx Corporation
Via Business Wire
Tickers CYTR
News headline image
CytRx Announces Centurion BioPharma Has Been Invited to Present Plans for a State-of-the-Art Cancer Center in Las Vegas, Nevada
From CytRx Corporation
Via Business Wire
Tickers CYTR
News headline image
CytRx Highlights Orphazyme's Update on Productive Meeting with FDA Regarding Arimoclomol in Niemann-Pick Disease Type C
From CytRx Corporation
Via Business Wire
Tickers CYTR
News headline image
CytRx Highlights ImmunityBio's Completion of Enrollment in Phase 2 Study of Advanced Metastatic Pancreatic Cancer Treatment
From CytRx Corporation
Via Business Wire
Tickers CYTR
News headline image
CytRx to Present at Upcoming Virtual LD Micro Conference
From CytRx Corporation
Via Business Wire
Tickers CYTR
News headline image
CytRx to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
From CytRx Corporation
Via Business Wire
Tickers CYTR
News headline image
CytRx Highlights Orphazyme’s Published Results From Its Phase 2/3 Trial of Arimoclomol in Niemann-Pick Disease Type C
From CytRx Corporation
Via Business Wire
Tickers CYTR ORPH
News headline image
CytRx Comments on Quarterly Results and Recent Strategic Initiatives
From CytRx Corporation
Via Business Wire
Tickers CYTR
News headline image
CytRx Announces Director Election Results from 2021 Annual Meeting of Stockholders
From CytRx Corporation
Via Business Wire
Tickers CYTR
News headline image
CytRx Highlights Preliminary Results of Cohort C of QUILT 88, a Phase 2 Pancreatic Cancer Trial That Includes Aldoxorubicin, Expected to be Released in Q1 2022
From CytRx Corporation
Via Business Wire
Tickers CYTR
News headline image
CytRx Corporation Announces Closing of $10 Million Offering to Healthcare-Focused Institutional Investor
From CytRx Corporation
Via Business Wire
Tickers CYTR
News headline image
CytRx Corporation Enters Into Securities Purchase Agreement for $10 Million With Healthcare-Focused Institutional Investor
From CytRx Corporation
Via Business Wire
Tickers CYTR
News headline image
CytRx Comments on Orphazyme’s Promising 24-Month Interim Trial Results of Arimoclomol for Niemann-Pick Disease Type C
From CytRx Corporation
Via Business Wire
Tickers CYTR
News headline image
CytRx Notes Orphazyme’s Regulatory Update from the FDA on Arimoclomol for Niemann-Pick Disease Type C
From CytRx Corporation
Via Business Wire
Tickers CYTR
News headline image
CytRx to Present at Upcoming Investor Conferences
From CytRx Corporation
Via Business Wire
Tickers CYTR
News headline image
CytRx Comments on Quarterly Results and Year-to-Date Progress
From CytRx Corporation
Via Business Wire
Tickers CYTR